Therapy Area topics
Cardiovascular
Vascepa's future could hinge on next week's panel
Amarin’s Vascepa is widely expected to receive approval in a huge new patient population. So why has the company not been bought?
Admedus moves from one unlikely area to another
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Central Nervous System
Upcoming events – Axsome takes on migraine and Kala looks to dry eye again
Axsome hopes to find a niche with its migraine project, AXS-07, while Kala's latest phase III needs to win over the regulators.
Diabetes
Upcoming events – Adamas and Ascendis look for new paths forward
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Digital Health
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Oncology
SITC – the morning after the night before
Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.
Ash 2019 preview – the first winner and losers emerge
Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Respiratory
Vertex’s double cystic fibrosis surprise
The remarkable speed of the company’s cystic fibrosis triplet approval will not distract attention from its price.
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Various
Go or no go? Agile and Lipocine hope to make it third time lucky
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.